Sequence variants of α-methylacyl-CoA racemase are associated with prostate cancer risk: A replication study in an ethnically homogeneous population

Prostate

Volumn 68, Issue 13, 2008, Pages 1373-1379

  FitzGerald, Liesel M ^a   Thomson, Russell ^a   Polanowski, Andrea ^a   Patterson, Briony ^a   McKay, James D ^b   Stankovich, James ^a,c   Dickinson, Joanne L ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Prostate cancer; Susceptibility gene variant

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BIOLOGICAL MARKER; ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE;

2 METHYLACYL COENZYME A RACEMASE GENE; AGED; ARTICLE; CANCER RISK; CONTROL GROUP; D175G GENE; DISEASE ASSOCIATION; FISHER EXACT TEST; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; M9V GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REPLICATION STUDY; RISK FACTOR; ADULT; AUSTRALIA; BLOOD; CASE CONTROL STUDY; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; TASMANIA;

EID: 50949094364     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20798     Document Type: Article

References (32)

1. Jiang Z, Woda BA, Yang XJ. Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer. JAMA 2002;287(23): 3080-3081; author reply 3081.
2. Leav I, McNeal JE, Ho SM, Jiang Z. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Hum Pathol 2003;34(3):228-233.
3. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002;62(8): 2220-2226.
4. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287(13):1662-1670.
5. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick TS, Leslie KB, Badaro R, Reed SG. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000;60(6):1677-1682.
6. Amery L, Fransen M, De Nys K, Mannaerts GP, Van Veldhoven PP. Mitochondrial and peroxisomal targeting of 2-methylacyl-CoA racemase m humans. J Lipid Res 2000;41(11):1752-1759.
7. Ferdinandusse S, Denis S, Ijlst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000;41(11):1890-1896.
8. Wanders RJ, Vreken P, Ferdinandusse S, Jansen GA, Waterham HR, van Roermund CW, Van Grunsven EG. Peroxisomal fatty acid alpha- and beta-oxidation in humans: Enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochem Soc Trans 2001;29(Pt 2):250-267.
9. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, Dunn RL, Chinnaiyan AM, Rubin MA. alpha-Methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002;161(3):841-848.
10. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, Kantoff PW, Johansson JE. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14(6):1424-1432.
11. Camp NJ, Farnham JM, Cannon Albright LA. Genomic search for prostate cancer predisposition loci in Utah pedigrees. Prostate 2005;65(4):365-374.
12. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001;68(5):1197-1206.
13. Hsieh CL, Oakley-Girvan I, Balise RR, Halpern J, Gallagher RP, Wu AH, Kolonel LN, O'Brien LE, Lin IG, Van Den Berg DJ, Teh CZ, West DW, Whittemore AS. A genome screen of families with multiple cases of prostate cancer: Evidence of genetic heterogeneity. Am J Hum Genet 2001;69(1):148-158.
14. Maier C, Herkommer K, Hoegel J, Vogel W, Paiss T. A genomewide linkage analysis for prostate cancer susceptibility genes in families from Germany. Eur J Hum Genet 2005;13(3): 352-360.
15. Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK, Wojno KJ, Cooney KA. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 2006;66(2): 173-179.
16. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274(5291):1371-1374.
17. Wiklund F, Gillanders EM, Albertus JA, Bergh A, Damber JE, Emanuelsson M, Freas-Lutz DL, Gildea DE, Goransson I, Jones MS, Jonsson BA, Lindmark F, Markey CJ, Riedesel EL, Stenman E, Trent JM, Gronberg H. Genome-wide scan of Swedish families with hereditary prostate cancer: Suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 2003;57(4):290-297.
18. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005;77(2):219-229.
19. Zheng SL, Chang BL, Faith DA, Johnson JR, Isaacs SD, Hawkins GA, Turner A, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. Cancer Res 2002;62(22):6485-6488.
20. Levin AM, Zuhlke KA, Ray AM, Cooney KA, Douglas JA. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. Prostate 2007;67(14): 1507-1513.
21. Lindstrom S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Balter KA, Brookes AJ, Sun J, Chang BL, Liu W, Li G, Isaacs WB, Adolfsson J, Gronberg H, Xu J. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate 2006; 66(16):1729-1743.
22. Daugherty SE, Shugart YY, Platz EA, Fallin MD, Isaacs WB, Pfeiffer RM, Welch R, Huang WY, Reding D, Hayes RB. Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer. Prostate 2007;67(14):1487- 1497.
23. Rubio JP, Bahlo M, Butzkueven H, van Der Mei IA, Sale MM, Dickinson JL, Groom P, Johnson LJ, Simmons RD, Tait B, Varney M, Taylor B, Dwyer T, Williamson R, Gough NM, Kilpatrick TJ, Speed TP, Foote SJ. Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis. Am J Hum Genet 2002;70(5):1125-1137.
24. Baird PN, Foote SJ, Mackey DA, Craig J, Speed TP, Bureau A. Evidence for a novel glaucoma locus at chromosome 3p 21-22. Hum Genet 2005;117(2-3):249-257.
25. McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L, Burgess J, Duffield A, Papotti M, Stark M, Sobol H, Maes B, Murat A, Kaariainen H, Bertholon-Gregoire M, Zini M, Rossing MA, Toubert ME, Bonichon F, Cavarec M, Bernard AM, Boneu A, Leprat F, Haas O, Lasset C, Schlumberger M, Canzian F, Goldgar DE, Romeo G. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001;69(2):440-446.
26. Thornton T, McPeek MS. Case-control association testing with related individuals: A more powerful quasi-likelihood score test. Am J Hum Genet 2007;81(2):321-337.
27. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70(2):425-434.
28. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11(5):863-874.
29. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31(13):3568-3571.
30. Mubiru JN, Shen-Ong GL, Valente AJ, Troyer DA. Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer. Gene 2004;327(1):89-98.
31. Mubiru JN, Valente AJ, Troyer DA. A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer. Prostate 2005;65(2):117-123.
32. Zha S, Isaacs WB. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer. Mol Cancer Res 2005;3(2):110-118.